Literature DB >> 7130396

Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.

P H Reitsma, S L Teitelbaum, O L Bijvoet, A J Kahn.   

Abstract

The bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl(2)MDP) effectively inhibit the accelerated bone resorption associated with some skeletal disorders, e.g., Paget's disease. However, it has not been established whether these compounds exert their inhibitory effect by rendering the bone mineral more resistant to degradation, by diminishing the activity of resorbing cells, or through some combination of both activities. In this study, we have tested these possibilities using an in vitro resorption assay system consisting of elicited rat peritoneal macrophages co-cultured with particles of (45)Ca-labeled, devitalized rat bone. This assay system permits the quantitative assessment of the action of APD and Cl(2)MDP on the two major phases of bone resorption (cell-substrate attachment and osteolysis) under circumstances where the drugs are present continuously or, most importantly for the issues in question, after the separate pretreatment of the particles or the resorbing cells. Our data indicate that (a) Both APD and Cl(2)MDP at concentrations >/=5 x 10(-6) M diminish macrophage-mediated (45)Ca release (i.e., bone resorption) in a log dose-dependent fashion. (b) A 10-min pretreatment of bone particles with either bisphosphonate (P-C-P) similarly inhibits resorptive activity, but is most pronounced with Cl(2)MDP. However, only APD is effective in reducing resorption when cells are preincubated (for 24 h) with P-C-P. (c) In cultures containing both labeled and unlabeled bone, significant inhibition occurs only when the labeled particles are coated with P-C-P (indicating that the action of P-C-P-treated bone is highly localized). (d) P-C-P does not diminish cell-bone particle attachment, an essential step in the resorptive process. On the other hand, delaying the addition of P-C-P until after cell-bone attachment is completed significantly reduces the resorption-inhibiting effect of these compounds. (e) Cl(2)MDP reduces culture DNA content in proportion to its inhibitory effect on resorption, and both the inhibitory and cytotoxic actions of this P-C-P are dependent upon the presence of bone. On the other hand, APD is cytotoxic only at very high concentrations (10(-4) M), acts independently of the presence of bone, and inhibits resorption without killing cells. We conclude that the mechanisms of action of APD and Cl(2)MDP are markedly different. Cl(2)MDP is a potent cytotoxin in the presence of bone and apparently exerts its inhibitory effect in this manner. APD is noncytotoxic at levels adequate to suppress resorption and, therefore, must inhibit macrophage activity by some other mechanism. Neither P-C-P appears to limit resorption by decreasing the solubility of mineralized bone matrix.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7130396      PMCID: PMC370305          DOI: 10.1172/jci110704

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  The alteration of osteoclast morphology by diphosphonates in bone organ culture.

Authors:  E J Rowe; E Hausmann
Journal:  Calcif Tissue Res       Date:  1976-04-13

Review 2.  Pyrophosphate and diphosphonates in skeletal metabolism. Physiological, clinical and therapeutic aspects.

Authors:  R G Russell; H Fleisch
Journal:  Clin Orthop Relat Res       Date:  1975-05       Impact factor: 4.176

3.  Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone.

Authors:  P J Meunier; M C Chapuy; C Alexandre; C Bressot; C Edouard; C Vignon; L Mathieu; U Trechsel
Journal:  Lancet       Date:  1979-09-08       Impact factor: 79.321

4.  The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals.

Authors:  A Jung; S Bisaz; H Fleisch
Journal:  Calcif Tissue Res       Date:  1973-03-30

5.  Improvements in the ethidium bromide method for direct fluorometric estimation of DNA and RNA in cell and tissue homogenates.

Authors:  U Karsten; A Wollenberger
Journal:  Anal Biochem       Date:  1977-02       Impact factor: 3.365

6.  Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  W B Frijlink; O L Bijvoet; J te Velde; G Heynen
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

7.  The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture.

Authors:  D K Fast; R Felix; C Dowse; W F Neuman; H Fleisch
Journal:  Biochem J       Date:  1978-04-15       Impact factor: 3.857

8.  Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats.

Authors:  R Schenk; W A Merz; R Mühlbauer; R G Russell; H Fleisch
Journal:  Calcif Tissue Res       Date:  1973-03-12

9.  The comparative effects of dichloromethylene diphosphonate (C12MDP) and ethane-1-hydroxy-1,1-diphosphonate (EHDP) on growth and modeling of the rat tibia.

Authors:  S C Miller; W S Jee
Journal:  Calcif Tissue Res       Date:  1977-10-20

10.  Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

View more
  29 in total

Review 1.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 2.  Advances in the management of Paget's disease of bone.

Authors:  D J Hosking
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro.

Authors:  A Carano; S L Teitelbaum; J D Konsek; P H Schlesinger; H C Blair
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

4.  Different schedules of administration of (3 amino-1-hydroxypropylidene)-1, 1 bisphosphonate induce different changes in pig bone remodeling.

Authors:  M C de Vernejoul; A Pointillart; C Bergot; J Bielakoff; C Morieux; A M Laval Jeantet; L Miravet
Journal:  Calcif Tissue Int       Date:  1987-03       Impact factor: 4.333

5.  Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

Authors:  M Sato; W Grasser; N Endo; R Akins; H Simmons; D D Thompson; E Golub; G A Rodan
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

6.  Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.

Authors:  Jason R Westin; Michael A Thompson; Vince D Cataldo; Luis E Fayad; Nathan Fowler; Michelle A Fanale; Saatva Neelapu; Felipe Samaniego; Jorge Romaguera; Jatin Shah; Peter McLaughlin; Barbara Pro; Larry W Kwak; Perpetua Sanjorjo; William A Murphy; Camillo Jimenez; Bela Toth; Wenli Dong; Fredrick B Hagemeister
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-12-29

Review 7.  Antitumour effects of bisphosphonates: first evidence and possible mechanisms.

Authors:  I J Diel
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 8.  Strategies for management of prostate cancer-related bone pain.

Authors:  R C Pelger; V Soerdjbalie-Maikoe; N A Hamdy
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

9.  Bisphosphonates inhibit 1,25-dihydroxyvitamin D3-induced increase of osteocalcin in plasma of rats in vivo and in culture medium of rat calvaria in vitro.

Authors:  S A Stronski; L Bettschen-Camin; A Wetterwald; R Felix; U Trechsel; H Fleisch
Journal:  Calcif Tissue Int       Date:  1988-04       Impact factor: 4.333

10.  Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo.

Authors:  Y Endo; M Nakamura; T Kikuchi; H Shinoda; Y Takeda; Y Nitta; K Kumagai
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.